Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
Improved anti-CD154 antibodies are provided herein which have ablated FcR binding. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
1. A human or humanized anti-CD154 antibody of the IgG1 isotype, wherein the Fc region of said antibody comprises an E269R mutation and a K322A mutation, wherein said mutations respectively eliminate FcR binding and C1Q binding.
2. The anti-CD 154 antibody of claim 1 , wherein said antibody comprises the identical V L complementarity determining regions (CDRs) as the humanized variable light chain polypeptides of SEQ ID NO: 6, and further comprises the identical V H CDRs as the humanized variable heavy chain polypeptides of—SEQ ID NO: 8.
3. The anti-CD154 antibody of claim 2 , wherein said antibody comprises a humanized variable light chain polypeptide selected from the variable light chain polypeptides of SEQ ID NO: 6, and the humanized variable heavy chain polypeptide of SEQ ID NO: 8.
4. The anti-CD 154 antibody of claim 2 , wherein said antibody comprises the humanized variable light chain polypeptide of SEQ ID NO: 4 and a humanized variable heavy chain polypeptide of SEQ ID NO: 8.
5. The anti-CD154 antibody of claim 1 , wherein said antibody comprises the humanized variable light chain polypeptide of SEQ ID NO: 6, and a humanized variable heavy chain polypeptide of SEQ ID NO: 8.
6. A pharmaceutical composition comprising a pharmaceutically effective amount of an antibody according to claim 1 .
7. A pharmaceutical composition comprising a pharmaceutically effective amount of an antibody according to claim 2 .
8. A pharmaceutical composition comprising a pharmaceutically effective amount of an antibody according to claim 3 .
9. A pharmaceutical composition comprising a pharmaceutically effective amount of an antibody according to claim 4 .
10. A pharmaceutical composition comprising a pharmaceutically effective amount of an antibody according to claim 5 .